Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 4Biliary Tract Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Neuroendocrine Tumor Grade 3 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Cisplatin 3surufatinib 2sintilimab 2lutetium Lu 177 dotatate 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Fluorodeoxyglucose F18 2Everolimus 2toripalimab 1copper dotatate CU-64 1Radiopharmaceuticals 1PE regimen 1Nivolumab 1Interferon-alpha 1IFL protocol 1Gemcitabine 1Fluorouracil 1Etoposide 1EC regimen 1Copper 1Carboplatin 1Capecitabine 1Bevacizumab 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Neuroendocrine × surufatinib × Clear all
NCT05747729 2023-02-28

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2 Unknown
60 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT05627427 2022-11-25

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinal

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡